The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Basifugin     (3S,6S,9S,12S,15S,18S,21S,24R, 27S)-3,6...

Synonyms: Basifungin, Aureobasidin-A, Aureobasidin A, KST-1A1034, CHEBI:1154292, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

High impact information on Aureobasidin-A

  • Moreover, lag1 Delta lac1 Delta cells are resistant to aureobasidin A, an inhibitor of the inositolphosphorylceramide synthase, suggesting that aureobasidin A may be toxic because it leads to increased ceramide levels [1].
  • Aureobasidin A, an inhibitor of the IPC synthase Aur1p completely blocks IPC biosynthesis at 0.5 micrograms/ml but does not block remodeling of glycosylphosphatidylinositol anchors even at concentrations up to 10 micrograms/ml [2].
  • Out of seven natural analogues and 18 chemical derivatives of AbA, several were shown to display even more potent Pgp-inhibitory activity [3].
  • In contrast, the most potent Pgp inhibitors were found among AbA analogues with [betaHO-MeVal(9)] residue alterations, with some data suggesting a negative impact of the [L-Leu(8)-L-betaHOMeVal(9)-D-Hmp(1)] gamma-turn secondary structure on Pgp inhibitory potential [3].
  • Treatment with LY295337, a depsipeptide with antifungal activity, was effective in prolonging survival and reducing fungal counts in brain tissue [4].

Biological context of Aureobasidin-A

  • Southern analysis of genomic DNAs of the transformants indicated that the copy number of the plasmid increased from one to more than four, depending on the concentration of AbA used for selection of the transformants [5].
  • A single point mutation in the aurA gene of A. nidulans confers a high level of resistance to aureobasidin A [6].
  • From a genomic library of one such AUR1 mutant, the AUR1R (for aureobasidin resistant) mutant gene was isolated as a gene that confers resistance to AbA on wild-type cells [7].
  • Syntheses of antifungal aureobasidin A analogs with alkyl chains for structure-activity relationship [8].
  • In order to investigate possible relationship between the molecular conformation and the amide N-methylation, aureobasidin A (AbA), which exhibits the potent antifungal activity, was subjected to X-ray crystal analysis [9].

Anatomical context of Aureobasidin-A


Associations of Aureobasidin-A with other chemical compounds

  • The [2,3-dehydro-MeVal(9)]-AbA was the most potent Pgp inhibitory aureobasidin, being 13-fold more potent than AbA and 19-fold more potent (on a molar basis) than CsA [3].
  • The resistance to aureobasidin A conferred by the MDR2/Pgp as well as by the MDR1/Pgp was overcome by vinblastine, verapamil, and cyclosporin A, depending on their concentrations, but not by colchicine [12].
  • The 2mu-based pCRE3 carries the aureobasidin A, zeocin and URA3 markers. pCRE3 proved to be easily cured without active counter-selection [13].
  • The minimum inhibitory concentration (MIC) was determined by the broth microdilution method for LY295337 in SDB and RPMI 1640, and for fluconazole by an agar dilution method [14].

Gene context of Aureobasidin-A

  • Mutations in AUR1 had been shown previously to give resistance to the antifungal drug aureobasidin A, leading us to predict that the drug should inhibit IPC synthase activity [15].
  • A N- and C-terminally truncated portion of the mutant FAS2 gene was subcloned to an integrating plasmid containing an aureobasidin A-resistant transformation marker and a galactose-inducible growth inhibitory sequence (GAL10p::GIN11) [16].


  1. Lag1p and Lac1p are essential for the Acyl-CoA-dependent ceramide synthase reaction in Saccharomyces cerevisae. Schorling, S., Vallée, B., Barz, W.P., Riezman, H., Oesterhelt, D. Mol. Biol. Cell (2001) [Pubmed]
  2. Biosynthesis of inositol phosphoceramides and remodeling of glycosylphosphatidylinositol anchors in Saccharomyces cerevisiae are mediated by different enzymes. Reggiori, F., Conzelmann, A. J. Biol. Chem. (1998) [Pubmed]
  3. Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter. Tiberghien, F., Kurome, T., Takesako, K., Didier, A., Wenandy, T., Loor, F. J. Med. Chem. (2000) [Pubmed]
  4. An alternative animal model for comparison of treatments for cryptococcal meningitis. Najvar, L.K., Bocanegra, R., Graybill, J.R. Antimicrob. Agents Chemother. (1999) [Pubmed]
  5. Transformation system for prototrophic industrial yeasts using the AUR1 gene as a dominant selection marker. Hashida-Okado, T., Ogawa, A., Kato, I., Takesako, K. FEBS Lett. (1998) [Pubmed]
  6. An aureobasidin A resistance gene isolated from Aspergillus is a homolog of yeast AUR1, a gene responsible for inositol phosphorylceramide (IPC) synthase activity. Kuroda, M., Hashida-Okado, T., Yasumoto, R., Gomi, K., Kato, I., Takesako, K. Mol. Gen. Genet. (1999) [Pubmed]
  7. AUR1, a novel gene conferring aureobasidin resistance on Saccharomyces cerevisiae: a study of defective morphologies in Aur1p-depleted cells. Hashida-Okado, T., Ogawa, A., Endo, M., Yasumoto, R., Takesako, K., Kato, I. Mol. Gen. Genet. (1996) [Pubmed]
  8. Syntheses of antifungal aureobasidin A analogs with alkyl chains for structure-activity relationship. Kurome, T., Inoue, T., Takesako, K., Kato, I. J. Antibiot. (1998) [Pubmed]
  9. Unique molecular conformation of aureobasidin A, a highly amide N-methylated cyclic depsipeptide with potent antifungal activity: X-ray crystal structure and molecular modeling studies. In, Y., Ishida, T., Takesako, K. J. Pept. Res. (1999) [Pubmed]
  10. Characterization of the inositol phosphorylceramide synthase activity from Trypanosoma cruzi. Figueiredo, J.M., Dias, W.B., Mendonça-Previato, L., Previato, J.O., Heise, N. Biochem. J. (2005) [Pubmed]
  11. Efficient selection of hybrids by protoplast fusion using drug resistance markers and reporter genes in Saccharomyces cerevisiae. Nakazawa, N., Iwano, K. J. Biosci. Bioeng. (2004) [Pubmed]
  12. Aureobasidin A, an antifungal cyclic depsipeptide antibiotic, is a substrate for both human MDR1 and MDR2/P-glycoproteins. Kino, K., Taguchi, Y., Yamada, K., Komano, T., Ueda, K. FEBS Lett. (1996) [Pubmed]
  13. Overproduction of pentose phosphate pathway enzymes using a new CRE-loxP expression vector for repeated genomic integration in Saccharomyces cerevisiae. Johansson, B., Hahn-Hägerdal, B. Yeast (2002) [Pubmed]
  14. Antifungal activity of LY295337 in vitro against clinical isolates of Candida spp. Aller, A.I., Martin Mazuelos, E., Morilla, M.D., Montero, O. Chemotherapy. (1995) [Pubmed]
  15. Sphingolipid synthesis as a target for antifungal drugs. Complementation of the inositol phosphorylceramide synthase defect in a mutant strain of Saccharomyces cerevisiae by the AUR1 gene. Nagiec, M.M., Nagiec, E.E., Baltisberger, J.A., Wells, G.B., Lester, R.L., Dickson, R.C. J. Biol. Chem. (1997) [Pubmed]
  16. Construction of recombinant sake yeast containing a dominant FAS2 mutation without extraneous sequences by a two-step gene replacement protocol. Akada, R., Matsuo, K., Aritomi, K., Nishizawa, Y. J. Biosci. Bioeng. (1999) [Pubmed]
WikiGenes - Universities